Business
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":"\n- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time -\n\n- Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference -\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022.\n\nEdgewise ARCH Interim Data Review Conference Call\n\nMembers of the Edgewise management team will hold a conference call and webcast on Tuesday, June 21, at 9:00 am ET to discuss the ARCH interim data. To participate, please dial 844-200-6205 (domestic) or 646-904-5544 (international) and refer to access code 260476. Visit the Edgewise events page to access the webcast, including replay and conference call slides.\n\nThe Company will have additional presentations and posters featuring EDG-5506 at the New Directions Conference and the 2022 PPMD Annual Conference, being held June 23-26, 2022. The presentations and posters will be available on the Edgewise website after they are presented.\n\n2022 New Directions in Biology and Disease of Skeletal Muscle Conference\nIndustry Workshop\nPresentation: Taking a New Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy: EDG-5506\nDate: Monday, June 20 at 12:10 p.m. ET\nPresenter: Joanne Donovan, M.D., Ph.D., Chief Medical Officer, Edgewise Therapeutics\n\nScientific Posters\nThe scientific posters listed below will be presented during Poster Session I on Wednesday, June 22, from 2 – 3:15 p.m. ET, and during Poster Session II on Thursday, June 23, from 7:30 – 9:45 a.m. ET.\n\nTitle: Skeletal Myosin Inhibitor EDG-5506 Protects Dystrophic Muscle from Contraction-Induced Injury\nTitle: Use of an Exercise Challenge System to Define a Universal Proteomic Signature of Muscle Injury in a Diverse Set of Adult Individuals with Inherited Myopathy\nTitle: Short-Term Proteomic Responses to the Fast Skeletal Myosin Inhibitor EDG-5506 in Becker Muscular Dystrophy\nTitle: EDG-55...